Metabolically Robust CYP-Eicosanoid Analogues for Ophthalmic Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current n-3 PUFA-derived CYP metabolites, such as 17,18-EEQ and 19,20-EDP, are not used as therapeutics due to their limited bioavailability and chemical instability, which hinders their effectiveness in treating or preventing disorders associated with neovascularization and inflammation, particularly ophthalmic disorders like age-related macular degeneration.
Innovation Solution
Development of metabolically robust analogues of n-3 PUFA metabolites, specifically compounds according to formula (VI) or their pharmaceutically acceptable salts, which are designed to be more stable and bioavailable for pharmaceutical formulation and administration, targeting neovascularization and inflammation-related disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If natural CYP metabolites (17,18-EEQ and 19,20-EDP) are used as therapeutics, then biological activity is achieved, but chemical stability and bioavailability are insufficient
Solution Approach 1:
The patent modifies the chemical structure of natural CYP metabolites by changing physical and chemical parameters such as replacing the epoxide group with alternative functional groups (e.g., diols, hydroxy acids, esters) to improve chemical stability while preserving biological activity. This structural parameter change allows the analogues to resist metabolic degradation while maintaining therapeutic efficacy.
Solution Approach 2:
The invention creates composite molecular structures by combining stable structural scaffolds with bioactive functional groups. The analogues integrate hydrophobic and hydrophilic regions, and stable carbon frameworks with reactive functional groups, to achieve both chemical stability and biological activity simultaneously.
2Reliability
If natural CYP metabolites (17,18-EEQ and 19,20-EDP) are used as therapeutics, then biological activity is achieved, but bioavailability is limited
Solution Approach 1:
The patent optimizes pharmacokinetic parameters by modifying molecular weight, lipophilicity, and solubility characteristics of the metabolites. The analogues are designed with improved absorption, distribution, metabolism, and excretion (ADME) properties to enhance bioavailability while maintaining biological activity.
Solution Approach 2:
The stable analogues act as intermediaries that can be administered systemically and then converted to active forms or directly exert therapeutic effects. The improved stability allows these compounds to serve as reliable mediators between administration and therapeutic action, overcoming the rapid degradation of natural metabolites.
3Reliability
If natural CYP metabolites are used, then anti-neovascularization and anti-inflammatory effects are achieved, but metabolic instability hinders therapeutic effectiveness
Solution Approach 1:
The patent extends the duration of action by modifying metabolic stability parameters. The analogues are designed to resist enzymatic degradation and metabolic transformation, thereby maintaining therapeutic concentrations for longer periods. This allows for less frequent dosing and sustained therapeutic effect.
Solution Approach 2:
The stable analogues provide sustained exposure to therapeutic levels of the active compound, ensuring that the biological effect is maintained throughout the dosing interval. The extended half-life allows for partial overlap of dosing cycles, ensuring continuous therapeutic coverage.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to compounds according to general formula (I) which are metabolically robust analogues of bioactive lipid mediators derived from omega-3 polyunsaturated fatty acids (n-3 PUFAs) for use in treating or reducing the risk of developing or preventing: (i) neovascularization and/or (ii) inflammatory disorder, in particular, ophthalmic disorders associated with neovascularization and/or inflammation.